Palo Alto, Calif. • 650-496-3777 • www.jazzpharmaceuticals.com
Ticker and Exchange: JAZZ: Nasdaq
Filing Range: 6.0M shares @ $24.00 to $26.00
Offering Price: $18.00
Close on First Day: $17.73
Offering Size: $108.00M
Shares Outstanding: 24,550,554
Underwriter: Morgan Stanley/ Lehman Brothers
Co-manager: Credit Suisse/ Natexis Bleichroeder Inc.
Company Counsel: Cooley Godward LLP
Manager Counsel: Davis Polk & Wardwell
Auditor: Ernst & Young LLP
Market Capitalization on 6/30/07: $392.81M
Close price at current month end: $16.00
Operates as a pharmaceutical company. The company is focus on applied research, product development and commercialization of neurological and psychiatric products. It creates new therapeutics by improving and expanding the uses of known compounds, and adding to pharmaceutical product portfolio through licensing, acquisitions and collaborations. Competitors include Eli Lilly, Pfizer Inc. and Forest Laboratories Inc.
Adams Street Partners, Beecken, Petty & Co., EGS Healthcare Capital Partners, Golden Gate Capital, Kohlberg, Kravis, Roberts & Co., Lehman Brothers, O Keefe Capital, Oak Hill Venture Partners, Prospect Venture Partners, Thoma Cressey Bravo, Versant Ventures.
Source: Thomson Financial